Insulin-like growth factor (
IGF)-I has
cancer promoting activities. However, the hypothesis that circulating
IGF-I concentration is related to risk of
lymphoma overall or its subtypes has not been examined prospectively.
IGF-I concentration was measured in pre-diagnostic plasma samples from a nested case-control study of 1,072 cases of lymphoid
malignancies and 1,072 individually matched controls from the European Prospective Investigation into
Cancer and Nutrition. Odds ratios (
ORs) and confidence intervals (CIs) for
lymphoma were calculated using conditional logistic regression.
IGF-I concentration was not associated with overall
lymphoma risk (multivariable-adjusted OR for highest versus lowest third = 0.77 [95% CI = 0.57-1.03], ptrend = 0.06). There was no statistical evidence of heterogeneity in this association with
IGF-I by sex, age at blood collection, time between blood collection and diagnosis, age at diagnosis, or body mass index (pheterogeneity for all ≥ 0.05). There were no associations between
IGF-I concentration and risk for specific BCL subtypes,
T-cell lymphoma or
Hodgkin lymphoma, although number of cases were small. In this European population,
IGF-I concentration was not associated with risk of overall
lymphoma. This study provides the first prospective evidence on circulating
IGF-I concentrations and risk of
lymphoma. Further prospective data are required to examine associations of
IGF-I concentrations with
lymphoma subtypes.